JW C&C Research Laboratories

JW C&C Research Laboratories is a premier drug discovery research institute based in South Korea, operating as a subsidiary of JW Pharmaceutical. Founded in 1992 as the first joint venture between Korean and Japanese pharma companies, it specializes in identifying first-in-class small molecule candidates using its proprietary CLOVER platform. The laboratory focuses on high-value therapeutic areas including oncology, immunology, and regenerative medicine. Its research engine has successfully produced several clinical-stage assets, including a selective STAT3 inhibitor and a histamine H4 receptor antagonist. The company continues to leverage its chemical genomics expertise to bridge the gap between basic research and clinical development.